Explore All 789 Divestiture Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | April 1, 2019 |
| Target | Arteaus Therapeutics - Emgality Royalty |
| Sector | Life Science |
| Buyer(s) | Royalty Pharma |
| Sellers(s) | Arteaus Therapeutics |
| Deal Type | Divestiture |
| Deal Value | 260M USD |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1996 |
| Sector | Business Services |
| Revenue | 2.3B USD (2024) |
Royalty Pharma is a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals, and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and three development-stage product candidates. Royalty Pharma was formed in 1996 and is based in New York, New York.
| Deal Context for Buyer | # |
|---|---|
| Overall | 2 of 3 |
| Sector: Life Science | 2 of 3 |
| Type: Divestiture | 2 of 3 |
| State: Massachusetts | 1 of 2 |
| Country: United States | 2 of 3 |
| Year: 2019 | 1 of 1 |
| Size (of disclosed) | 2 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-02-27 |
TYSABRI
United States TYSABRI (natalizumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) to slow the worsening of symptoms common in people with MS and to decrease the number of flare-ups (relapses). TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML). When starting and continuing treatment with TYSABRI, it is important to discuss with your doctor whether the expected benefit of TYSABRI is enough to outweigh this risk. |
Buy | $2.9B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-04-08 |
Dicerna - OXLUMO™
Lexington, Massachusetts, United States Dicerna's OXLUMO has been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of primary hyperoxaluria (PH) type 1. |
Buy | $240M |
Arteaus Therapeutics LLC is a biotechnology development company. Arteaus Therapeutics LLC is based in Cambridge, Massachusetts.
| Deal Context for Seller | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science | 1 of 1 |
| Type: Divestiture | 1 of 1 |
| State: Massachusetts | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2019 | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
